全文获取类型
收费全文 | 15506篇 |
免费 | 1114篇 |
国内免费 | 128篇 |
专业分类
耳鼻咽喉 | 136篇 |
儿科学 | 466篇 |
妇产科学 | 454篇 |
基础医学 | 2431篇 |
口腔科学 | 276篇 |
临床医学 | 1283篇 |
内科学 | 3624篇 |
皮肤病学 | 380篇 |
神经病学 | 2205篇 |
特种医学 | 427篇 |
外科学 | 1440篇 |
综合类 | 28篇 |
一般理论 | 1篇 |
预防医学 | 838篇 |
眼科学 | 171篇 |
药学 | 1096篇 |
中国医学 | 32篇 |
肿瘤学 | 1460篇 |
出版年
2023年 | 191篇 |
2022年 | 169篇 |
2021年 | 637篇 |
2020年 | 400篇 |
2019年 | 494篇 |
2018年 | 648篇 |
2017年 | 471篇 |
2016年 | 541篇 |
2015年 | 604篇 |
2014年 | 739篇 |
2013年 | 974篇 |
2012年 | 1392篇 |
2011年 | 1394篇 |
2010年 | 782篇 |
2009年 | 709篇 |
2008年 | 1170篇 |
2007年 | 1060篇 |
2006年 | 960篇 |
2005年 | 854篇 |
2004年 | 782篇 |
2003年 | 689篇 |
2002年 | 526篇 |
2001年 | 54篇 |
2000年 | 33篇 |
1999年 | 53篇 |
1998年 | 82篇 |
1997年 | 53篇 |
1996年 | 37篇 |
1995年 | 41篇 |
1994年 | 44篇 |
1993年 | 22篇 |
1992年 | 18篇 |
1991年 | 18篇 |
1990年 | 16篇 |
1989年 | 15篇 |
1988年 | 7篇 |
1987年 | 10篇 |
1986年 | 10篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1980年 | 7篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Simonetta Viviani Arabella Mazzocchi Chiara Pavoni Francesca Taverna Andrea Rossi Caterina Patti Alessandra Romano Livio Trentin Roberto Sorasio Anna Guidetti Daniela Gottardi Corrado Tarella Michele Cimminiello Roberta Zanotti Lucia Farina Andrés José Maria Ferreri Marina Galbiati Paolo Corradini Alessandro Massimo Gianni Andrea Gallamini Alessandro Rambaldi 《Hematological oncology》2020,38(4):501-508
Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). In 266 patients with available serum samples, who have agreed to participate in a sub-study for assessment of the role of TARC monitoring, serum TARC levels were measured at baseline and at time of PET-2 by commercially available ELISA test kits. The primary end-point was to evaluate the association between TARC after 2 ABVD cycles and PFS. Median TARC-2 values were significantly higher in PET-2-positive patients compared to PET-2-negative patients (P = .001), and in patients with treatment failure compared to those in continuous CR (P = .01). The 4-year PFS significantly differed between patients with TARC-2 >800 pg/mL vs ≤800 pg/mL (64% vs 86%, P = .0001). Moreover, among PET-2-negative patients, elevated TARC-2 identified those with a worse prognosis (74% vs 89%; P = .01). In multivariable analysis, TARC-2 >800 pg/mL was a significant independent predictor of PFS in the whole study population (HR 2.39, P = .004) and among the PET-2-negative patients (HR 2.49, P = .02). In conclusion, our results indicate that TARC-2 serum levels above 800 pg/mL suggest the need for a stringent follow-up in PET-2-negative patients, and the evaluation of new drugs in PET-2-positive, who will likely fail to respond to intensification with escalated BEACOPP. 相似文献
12.
Paolo Fontana Francesco Fioravanti Passaretti Marianna Maioli Giuseppina Cantalupo Francesca Scarano Fortunato Lonardo 《World Journal of Medical Genetics》2020,9(1):1-11
Wiedemann-Steiner syndrome (OMIM #605130) is a rare congenital malformation syndrome characterized by hypertrichosis cubiti associated with short stature; consistent facial features, including long eyelashes, thick or arched eyebrows with a lateral flare, wide nasal bridge, and downslanting and vertically narrow palpebral fissures; mild to moderate intellectual disability; behavioral difficulties; and hypertrichosis on the back. It is caused by heterozygous pathogenic variants in KMT2A. This gene has an established role in histone methylation, which explains the overlap of Wiedemann-Steiner syndrome with other chromatinopathies, a heterogeneous group of syndromic conditions that share a common trigger: The disruption of one of the genes involved in chromatin modification, leading to dysfunction of the epigenetic machinery. 相似文献
13.
Elena Andreucci Anna Laurenzana Silvia Peppicelli Alessio Biagioni Francesca Margheri Jessica Ruzzolini Francesca Bianchini Gabriella Fibbi Mario Del Rosso Chiara Nediani Simona Serratì Livia Fucci Michele Guida Lido Calorini 《Oncology research》2020,28(9):873-884
Malignant melanoma is a highly aggressive skin cancer characterized by an elevated grade of tumor cell plasticity. Such plasticity allows adaptation of melanoma cells to different hostile conditions and guarantees tumor
survival and disease progression, including aggressive features such as drug resistance. Indeed, almost 50% of
melanoma rapidly develop resistance to the BRAFV600E inhibitor vemurafenib, with fast tumor dissemination,
a devastating consequence for patients’ outcomes. Vasculogenic mimicry (VM), the ability of cancer cells to
organize themselves in perfused vascular-like channels, might sustain tumor spread by providing vemurafenibresistant cancer cells with supplementary ways to enter into circulation and disseminate. Thus, this research
aims to determine if vemurafenib resistance goes with the acquisition of VM ability by aggressive melanoma
cells, and identify a driving molecule for both vemurafenib resistance and VM. We used two independent
experimental models of drug-resistant melanoma cells, the first one represented by a chronic adaptation of
melanoma cells to extracellular acidosis, known to drive a particularly aggressive and vemurafenib-resistant
phenotype, the second one generated with chronic vemurafenib exposure. By performing in vitro tube formation assay and evaluating the expression levels of the VM markers EphA2 and VE-cadherin by Western blotting
and flow cytometer analyses, we demonstrated that vemurafenib-resistant cells obtained by both models are
characterized by an increased ability to perform VM. Moreover, by exploiting the CRISPR-Cas9 technique and
using the urokinase plasminogen activator receptor (uPAR) inhibitor M25, we identified uPAR as a driver of
VM expressed by vemurafenib-resistant melanoma cells. Thus, uPAR targeting may be successfully leveraged
as a new complementary therapy to inhibit VM in drug-resistant melanoma patients, to counteract the rapid
progression and dissemination of the disease. 相似文献
14.
15.
Ernesto Caffo Francesca Scandroglio Lisa Asta 《Child and Adolescent Mental Health》2020,25(3):167-168
Italy was the first country in Europe to deal with COVID-19. Measures taken by the government to contain the spread of the virus were based mainly on quarantine and social distancing, with dramatic economic, social and psychological consequences. Since March, Italian children and adolescents are facing school closures, which have caused a disruption in the daily lives of millions of young people and their families. To date, despite the slow reopening, the government has decided to maintain school closures for the entire academic year, leaving the future of young people in uncertainty. There is already some evidence that quarantine and social isolation are having negative impact on children's and adolescents' psychological well-being. Moreover, this situation will mainly affect those children and adolescents with pre-existing vulnerabilities and those suffering of mental disorders. It is imperative to keep young people’s needs at the core of reconstruction plans, allowing them to return to school safely, and providing them with some strategies to heal and dealing with this stressful and potentially traumatic situation. 相似文献
16.
Erika Borlenghi Chiara Cattaneo Elisa Cerqui Silvana Archetti Diego Bertoli Daniela Bellotti Doriana Gramegna Giulia Soverini Margherita Oberti Francesca Schieppati Chiara Pagani Angela Passi Margherita Sciumé Mirko Farina Cecilia Carbone Claudia Crippa Daniela Dalceggio Alessandra Tucci Giuseppe Rossi 《Hematological oncology》2020,38(5):754-762
Consolidation treatment in acute myeloid leukemia (AML) patients achieving complete remission (CR) is warranted. High-dose cytarabine (HDAC) is considered first choice in favorable risk and an option in intermediate-risk AML. However, its optimal dose and schedule, as well as the benefit of additional chemotherapy agents remain controversial. Herein, we report on the long-term outcome of consecutive unselected AML patients treated with repeated courses of HDAC, with the addition of idarubicin, followed by autologous peripheral blood stem cell (PBSC) support, in order to limit toxicity, according to Northern Italy Leukemia Group (NILG) AML-01/00 study (EUDRACT number 00400673). Among 338 patients consecutively diagnosed from 2001 to 2017 at our center, 148 with high-risk AML (adverse cytogenetic, isolated FLT3-internal tandem duplication mutation, refractory to first induction) were addressed to allogeneic stem cell transplant. All other cases, 186 patients (55%), median age 53 (range 19–75), were considered standard-risk and received the NILG AML-01/00 program. After achieving CR, patients were mobilized with cytarabine 8 g/sqm to collect autologous CD34+-PBSC and received three consolidation cycles with HDAC (20 g/sqm) plus idarubicin (20 mg/sqm) per cycle, followed by reinfusion of limited doses of CD34+ PBSC (1-2x106/kg). The program was completed by 160 (86%) patients. Toxicity was acceptable. Neutrophils recovered a median of 10 days. Treatment-related mortality was 3/160 (1.8%). After a median follow-up of 66.4 months, overall survival (OS) and relapse-free survival (RFS) at 5-years were 61.4% and 52.4%, respectively. Twenty-eight selected patients aged >65 had similar outcomes. According to European leukemia net-2010 classification, the OS and RFS at 5-years were 76.4% and 65% in favorable risk, without differences between molecular subgroups, 52.3% and 47.2% in Intermediate-I, 45.2% and 36.5% in Intermediate-II risk patients, respectively. In conclusion, consolidation including repeated courses of high dose cytarabine and idarubicin, with limited PBSC support, proved feasible and very effective in nonhigh risk patients. The incorporation of novel agents in its backbone may be tested to further improve patient's prognosis. 相似文献
17.
18.
19.
Filippo Pietrantonio Fotios Loupakis Giovanni Randon Alessandra Raimondi Massimiliano Salati Dario Trapani Filippo Pagani Ilaria Depetris Giulia Maddalena Federica Morano Salvatore Corallo Michele Prisciandaro Francesca Corti Vincenzo Guarini Alessandro Bocconi Antonio Marra Carmen Belli Andrea Spallanzani Matteo Fassan Sara Lonardi Giuseppe Curigliano Giovanni Fucà Maria Di Bartolomeo Filippo de Braud 《The oncologist》2020,25(9):803-809
20.
Since the discovery of the presence of fibrillary forms ofα-synuclein(α-syn)in Lewy bodies(LB)and Lewy neurites in the brain of patients affected by Parkinson’s disease(PD)and dementia with LB,great effort has been dedicated to study the features ofα-syn fibrillation.In parallel,the pathological relevance of the different toxic forms ofα-syn has been also matter of investigation.In the last twenty years,scientists have been able to single out thatα-syn fibrillation initiates pathological mechanisms that by contributing to or triggering neurodegeneration/neuroinflammation,may lead to PD pathogenesis.This notwithstanding,we still ignore the reasons whyα-syn shifts from its natively unfolded conformation to toxic oligomeric and fibrillary forms.The chameleonic nature of monomericα-syn,and the extremely polymorphic characteristics of aggregated strains,renders it difficult to picture the real nature ofα-syn fibrils,their exact composition and formation dynamics.Recently,sophisticated biophysical methods and microscopy techniques have been exploited to studyα-syn fibrillation.Here,we provide an overview of the most relevant advancement in our understanding ofα-syn fibrils formation and conformation. 相似文献